- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Pivot Pharma and Solmic Research GmbH Sign Agreement
Pivot Pharmaceuticals alongside its medical cannabis division announced an agreement with Solmic Research GmbH to acquire the worldwide rights to Solmic Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts.
Pivot Pharmaceuticals (OTCQB:PVOTF) alongside its medical cannabis division announced an agreement with Solmic Research GmbH to acquire the worldwide rights to Solmic Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts.
As quoted in the press release:
Solmic’s proprietary technology provides significantly higher bioavailability and stability compared to alternative oil-based formulations.
“Solmic is pleased to partner with Pivot’s experienced management team to develop water-soluble products containing cannabinoid natural extracts. Our proprietary technology will solve many issues that are faced by the fast-developing medical cannabis industry. By increasing bioavailability and stability, patients will be able to confidently take correct and accurate doses of oral solutions to help with their therapeutic needs,” states Solmic CEO Dr. Wolfgang Schoenfeld.
Click here to read the full press release.
Source: www.marketwired.com
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.